Physician profile
Jill Davis
NPI 1316044746
$598.15
in general payments reported to CMS, 2019-2025
14 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $41.79 · 2024: $46.86 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $187.28 | 2024-2025 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $72.43 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $58.95 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $50.48 | 2025 | |
| Amgen INC. | $41.37 | 2025 | Krystexxa, Evenity |
| Harmony Biosciences LLC | $35.24 | 2025 | |
| Exact Sciences Corporation | $31.31 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $22.00 | 2025 | Mounjaro |
| Boston Scientific Corporation | $19.00 | 2025 | Watchman Access System |
| Pfizer INC. | $17.94 | 2025 | |
| Abbott Laboratories | $16.96 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals Lp | $16.04 | 2025 | Farxiga |
| Lundbeck LLC | $15.00 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.15 | 2025 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.